Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) by 139.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 698,255 shares of the company’s stock after purchasing an additional 406,891 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Neumora Therapeutics were worth $9,224,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the business. Callan Capital LLC grew its position in shares of Neumora Therapeutics by 222.6% during the 2nd quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock valued at $6,500,000 after buying an additional 456,207 shares during the last quarter. Auour Investments LLC acquired a new position in Neumora Therapeutics in the third quarter valued at approximately $3,302,000. Bank of New York Mellon Corp boosted its stake in Neumora Therapeutics by 474.1% in the second quarter. Bank of New York Mellon Corp now owns 235,593 shares of the company’s stock valued at $2,316,000 after acquiring an additional 194,559 shares during the period. Marshall Wace LLP bought a new position in shares of Neumora Therapeutics during the second quarter valued at approximately $1,323,000. Finally, Rhumbline Advisers raised its position in shares of Neumora Therapeutics by 488.3% during the 2nd quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock worth $1,015,000 after purchasing an additional 85,706 shares during the period. Institutional investors own 47.65% of the company’s stock.

Insiders Place Their Bets

In related news, insider Robert A. Lenz sold 30,788 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the completion of the transaction, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. This represents a 8.32 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The stock was sold at an average price of $17.03, for a total transaction of $239,254.47. Following the sale, the director now owns 20,100 shares in the company, valued at $342,303. This represents a 41.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,400 shares of company stock valued at $686,361 in the last three months. Company insiders own 26.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. cut shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $18.00 to $15.00 in a report on Tuesday, November 5th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research report on Friday, November 22nd. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $21.67.

Neumora Therapeutics Trading Up 0.8 %

NMRA stock opened at $10.37 on Tuesday. The firm has a 50-day moving average of $12.37 and a two-hundred day moving average of $11.49. The firm has a market capitalization of $1.68 billion, a PE ratio of -5.55 and a beta of 3.37. Neumora Therapeutics, Inc. has a one year low of $8.33 and a one year high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same quarter in the prior year, the business posted ($1.14) earnings per share. On average, equities research analysts anticipate that Neumora Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.